• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients.

作者信息

Saito Kazutaka, Fujii Yasuhisa

机构信息

Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan.

Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan.

出版信息

Eur Urol. 2018 Jul;74(1):46-47. doi: 10.1016/j.eururo.2017.09.038. Epub 2017 Oct 21.

DOI:10.1016/j.eururo.2017.09.038
PMID:29066029
Abstract
摘要

相似文献

1
Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients.醋酸阿比特龙之后恩杂鲁胺的抗肿瘤活性及安全性：探寻去势抵抗性前列腺癌患者的最佳治疗顺序
Eur Urol. 2018 Jul;74(1):46-47. doi: 10.1016/j.eururo.2017.09.038. Epub 2017 Oct 21.
2
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.在欧洲，对于之前接受醋酸阿比特龙联合泼尼松治疗≥24 周的转移性去势抵抗性前列腺癌患者，恩杂鲁胺的抗肿瘤活性和安全性。
Eur Urol. 2018 Jul;74(1):37-45. doi: 10.1016/j.eururo.2017.07.035. Epub 2017 Aug 23.
3
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.转移性去势抵抗性前列腺癌中恩扎卢胺和醋酸阿比特龙联合泼尼松序贯治疗的最佳顺序：一项多中心、随机、开放标签、2 期、交叉试验。
Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11.
4
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.恩杂鲁胺联合醋酸阿比特龙治疗骨转移去势抵抗性前列腺癌患者。
Eur Urol Oncol. 2020 Feb;3(1):119-127. doi: 10.1016/j.euo.2019.01.008. Epub 2019 Apr 20.
5
Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis.醋酸阿比特龙联合泼尼松与恩扎卢胺治疗去势抵抗性转移性前列腺癌的最佳治疗序贯：系统评价和荟萃分析。
Cancer Treat Rev. 2021 Feb;93:102152. doi: 10.1016/j.ctrv.2020.102152. Epub 2021 Jan 11.
6
Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.化疗初治转移性去势抵抗性前列腺癌患者接受恩杂鲁胺或醋酸阿比特龙治疗的治疗持续时间、医疗资源利用和成本：一项回顾性索赔分析。
Adv Ther. 2018 Oct;35(10):1639-1655. doi: 10.1007/s12325-018-0774-1. Epub 2018 Sep 6.
7
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.阿比特龙治疗后化疗初治转移性去势抵抗性前列腺癌患者应用恩扎卢胺的疗效。
Eur Urol. 2015 Jan;67(1):23-29. doi: 10.1016/j.eururo.2014.06.045. Epub 2014 Jul 10.
8
Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.多西他赛后进展的转移性去势抵抗性前列腺癌二线治疗药物的疗效和安全性：一项系统评价和荟萃分析。
Arch Ital Urol Androl. 2015 Jul 7;87(2):121-9. doi: 10.4081/aiua.2015.2.121.
9
Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.醋酸阿比特龙和恩杂鲁胺治疗转移性去势抵抗性前列腺癌患者的每月中位总生存期成本。
J Med Econ. 2016 Aug;19(8):777-84. doi: 10.3111/13696998.2016.1173042. Epub 2016 Apr 20.
10
Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.转移性、去势抵抗性、多西他赛耐药性前列腺癌的治疗：一项基于随机临床试验网络荟萃分析的文献系统评价
Rev Recent Clin Trials. 2018;13(3):226-237. doi: 10.2174/1574887113666180404120540.

引用本文的文献

1
Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration-Resistant Prostate Cancer.用于预测阿比特龙治疗结果和选择去势抵抗性前列腺癌替代疗法的生物标志物。
Clin Pharmacol Ther. 2022 Jun;111(6):1296-1306. doi: 10.1002/cpt.2582. Epub 2022 Apr 12.
2
The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression.JNK抑制剂AS602801与恩杂鲁胺协同作用，在体外和体内杀死前列腺癌细胞并抑制雄激素受体表达。
Transl Oncol. 2020 Apr;13(4):100751. doi: 10.1016/j.tranon.2020.100751. Epub 2020 Mar 18.